Steenhoek Adri, Koopmanschap Marc A, Franken Margreet G, Rutten Frans F H
Erasmus Universiteit Rotterdam, Instituut Beleid & Management Gezondheidszorg, Sectie Gezondheidseconomie, Rotterdam, the Netherlands.
Ned Tijdschr Geneeskd. 2011;155:A2042.
When a new medical technology, for example a new drug, is introduced onto the market there should be a discussion of the balance between "uncertainty versus value to society and demand". The new technology is sometimes given the benefit of the doubt due to a lack of information. Follow-up investigation is actually essential but is seldom mandatory and hardly ever spontaneously initiated. Specific measures, based on stimulation or penalization, could reduce the degree of uncertainty concerning the efficacy, safety and efficiency of a new technology. A serious option when a new drug produces disappointing results is to pay the manufacturer less.
当一种新的医疗技术，例如一种新药，投放市场时，应该对“不确定性与对社会的价值和需求”之间的平衡进行讨论。由于缺乏信息，新技术有时会被给予疑罪从无的待遇。后续调查实际上至关重要，但很少是强制性的，而且几乎从未自发开展过。基于激励或惩罚的具体措施，可以降低新技术在疗效、安全性和效率方面的不确定性程度。当一种新药产生令人失望的结果时，一个严肃的选择是减少向制造商付款。
